# Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

> **NCT02430350** · PHASE3 · COMPLETED · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 1200 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Compound Edaravone Injection
- **DRUG:** Edaravone Injection

## Key facts

- **NCT ID:** NCT02430350
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 1200 (ACTUAL)
- **Last updated:** 2017-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02430350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02430350, "Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02430350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*